NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
Hoffmann-La Roche
Astellas Pharma Inc
Eisai Inc.
University Health Network, Toronto
M.D. Anderson Cancer Center
Effector Therapeutics
Hoffmann-La Roche
PharmaMar
Eli Lilly and Company
Eli Lilly and Company
National University Hospital, Singapore
Children's Medical Center Dallas